Overview

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Status:
Completed
Trial end date:
2006-06-15
Target enrollment:
Participant gender:
Summary
A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Sitagliptin Phosphate